Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

The present protocol establishes a peritoneal dialysis (PD) mouse model of chlorhexidine gluconate (CG)-induced peritoneal fibrosis. The current model is simple and easy to use compared to other PD animal models.

Abstract

Peritoneal fibrosis is an important complication of peritoneal dialysis (PD). To investigate and address this problem, an appropriate animal model of PD is required. The present protocol establishes a chlorhexidine gluconate (CG) induced peritoneal fibrosis model that mimics the condition of a patient with PD. Peritoneal fibrosis was induced by intraperitoneal injection of 0.1% of CG in 15% ethanol for 3 weeks (administered every other day), for a total of nine times in male C57BL/6 mice. Peritoneal functional tests were then performed on day 22. After the mice were sacrificed, the parietal peritoneum of the abdominal wall and the visceral peritoneum of the liver were harvested. They were thicker and more fibrotic when analyzed microscopically after Masson's trichrome staining. The ultrafiltration rate decreased, and glucose mass transport indicated a CG-induced increase in peritoneal permeability. The PD model thus established may have applications in improving PD technology, dialysis efficacy, and prolonging patient survival.

Introduction

Peritoneal dialysis (PD) is a type of renal replacement therapy. However, PD has problems that cannot be solved. For example, long-term PD treatment can cause peritoneal damage, eventually leading to ultrafiltration failure and withdrawal of treatment1,2,3,4,5,6. Peritoneal fibrosis is one of the most serious complications7,8. Peritoneal fibrosis is characterized by the deposition and accumulation of extracellular ....

Protocol

All mouse experiments were approved by the Laboratory Animal Center of the E-DA Hospital/ I-Shou University and were handled according to the "Guide for the Care and Use of Laboratory Animals" (NRC, USA 2011). Male C57BL/6 mice, 7-8 weeks old, were used for the present study.

1. Chemical preparation

  1. Prepare the chemical irritant by diluting 0.1% chlorhexidine gluconate (CG, see Table of Materials) in 15% ethanol.

Representative Results

In Figure 1A,B, the parietal peritoneum of the abdominal wall was markedly thicker and more fibrotic under Masson's trichrome staining17, indicating that in the CG-exposed group, peritoneal fibrosis is more severe than in the control saline group (NS). In Figure 2A,B, the visceral peritoneum of the liver surfaces was also markedly thicker and more fibrotic, thus proving that in the CG-exposed group, p.......

Discussion

In this study, a mouse PD model is presented by i.p. injection of CG, and the results showed peritoneal fibrosis and functional deterioration in this model, which mimicked the PD patient's condition.

There are several critical steps in the protocol. First, for performing an i.p. injection of CG or NS, the abdominal wall skin of the mouse must be picked up using forceps to prevent puncture-induced intraperitoneal organ damage. Second, while collecting the peritoneum of the abdominal wall fo.......

Acknowledgements

We sincerely thank Shin-Han Tseng for the critical discussion and partial execution of the study. This study was supported by EDAHP110003 and NCKUEDA110002 from the Research Foundation of E-DA Hospital and the National Cheng Kung University, Taiwan.

....

Materials

NameCompanyCatalog NumberComments
0.9% Normal SalineY F CHEMICAL CORP., New Taipei City, Taiwan-
10% neutral buffered formalinTaiwan Burnett International Co., Ltd., Taipei City, Taiwan00002A
Automatic biochemical analyzerHitachi Ltd., Tokyo, JapanLabospect Series 008for determining glucose concentration
Chlorhexidine digluconate solution, 20% in H2OSigma-Aldrich, MO, USAC9394diluted to 0.1% with 15% ethanol for injection
EthanolAvantor Performance Materials, LLC, PA, USABAKR8006-05diluted to 15% with normal saline for working concentration
Glucose (Dianeal)Baxter International, Inc., IL, USAFNB9896Commercial dialysis solution (4.25%)
GraphPad Prism 8.0GraphPad Software, Inc., CA, US
L-type Glu 2 assayFUJIFILM Wako, Japan461-32403
Xylazine 20Juily Pharmaceutical Co., Ltd., New Taipei City, Taiwan-
Zoletil 50Virbac Laboratories, Carros, France-

References

  1. Han, S. H., et al. Improving outcome of CAPD: twenty-five years' experience in a single Korean center. Peritoneal Dialysis International. 27 (4), 432-440 (2007).
  2. Kawaguchi, Y., Hasegawa, T., Nakayama, M., Kubo, H., Shigematu, T.

Explore More Articles

Peritoneal DialysisPDMouse ModelChlorhexidine GluconatePeritoneal FibrosisPeritoneal Function TestDialysis SolutionMasson s Trichrome StainingVisceral PeritoneumParietal Peritoneum

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved